Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 73

Similar articles for PubMed (Select 21778168)

1.

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.

Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G, Pao W.

Eur Respir J. 2012 Feb;39(2):366-72. doi: 10.1183/09031936.00010111. Epub 2011 Jul 20.

2.

Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.

Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I.

J Thorac Oncol. 2006 Mar;1(3):231-9.

PMID:
17409862
3.

Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.

Leidner RS, Fu P, Clifford B, Hamdan A, Jin C, Eisenberg R, Boggon TJ, Skokan M, Franklin WA, Cappuzzo F, Hirsch FR, Varella-Garcia M, Halmos B.

J Clin Oncol. 2009 Nov 20;27(33):5620-6. doi: 10.1200/JCO.2009.23.1431. Epub 2009 Sep 28.

4.

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF.

J Natl Cancer Inst. 2005 Mar 2;97(5):339-46.

5.

Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic malaysian patient population.

Liam CK, Leow HR, How SH, Pang YK, Chua KT, Lim BK, Lai NL, Kuan YC, Pailoor J, Rajadurai P.

Asian Pac J Cancer Prev. 2014;15(1):321-6.

6.

Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.

Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastri AD, Soff GA, Schwartz AG, Sima CS, Ayalew G, Lau C, Zakowski MF, Rusch VW, Ladanyi M, Kris MG.

J Thorac Oncol. 2011 Jan;6(1):28-31. doi: 10.1097/JTO.0b013e3181fb4fe2.

7.

[Epidermal growth factor receptor mutation in Chinese patients with non-small cell lung cancer].

Pan ZK, Zhang L, Zhang X, Wang X, Li N, Xu F, Chang JH, Guan ZZ.

Ai Zheng. 2005 Aug;24(8):919-23. Chinese.

PMID:
16086866
8.
9.

Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer.

Hsieh RK, Lim KH, Kuo HT, Tzen CY, Huang MJ.

Chest. 2005 Jul;128(1):317-21.

PMID:
16002952
10.
11.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

PMID:
21258250
12.

Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.

Nishie K, Kawaguchi T, Tamiya A, Mimori T, Takeuchi N, Matsuda Y, Omachi N, Asami K, Okishio K, Atagi S, Okuma T, Kubo A, Maruyama Y, Kudoh S, Takada M.

J Thorac Oncol. 2012 Nov;7(11):1722-7. doi: 10.1097/JTO.0b013e31826913f7.

PMID:
23059777
13.

Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer.

Cote ML, Haddad R, Edwards DJ, Atikukke G, Gadgeel S, Soubani AO, Lonardo F, Bepler G, Schwartz AG, Ethier SP.

J Thorac Oncol. 2011 Mar;6(3):627-30. doi: 10.1097/JTO.0b013e31820a0ec0.

14.

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.

Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM.

Clin Cancer Res. 2005 May 15;11(10):3750-7.

15.
16.

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.

Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC.

Cancer. 2012 Feb 1;118(3):729-39. doi: 10.1002/cncr.26311. Epub 2011 Jun 30.

17.

EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.

Bae NC, Chae MH, Lee MH, Kim KM, Lee EB, Kim CH, Park TI, Han SB, Jheon S, Jung TH, Park JY.

Cancer Genet Cytogenet. 2007 Mar;173(2):107-13.

PMID:
17321325
18.

Genotyping non-small cell lung cancer (NSCLC) in Latin America.

Arrieta O, Cardona AF, Federico Bramuglia G, Gallo A, Campos-Parra AD, Serrano S, Castro M, Avilés A, Amorin E, Kirchuk R, Cuello M, Borbolla J, Riemersma O, Becerra H, Rosell R; CLICaP.

J Thorac Oncol. 2011 Nov;6(11):1955-9. doi: 10.1097/JTO.0b013e31822f655f.

PMID:
22005474
19.

High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.

Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, Jheon S, Lee CT, Lee JS, Chung JH.

J Thorac Oncol. 2012 Feb;7(2):323-30. doi: 10.1097/JTO.0b013e3182381515.

PMID:
22237264
20.

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach.

Salto-Tellez M, Tsao MS, Shih JY, Thongprasert S, Lu S, Chang GC, Au JS, Chou TY, Lee JS, Shi YK, Radzi A, Kang JH, Kim SW, Tan SY, Yang JC.

J Thorac Oncol. 2011 Oct;6(10):1663-9. doi: 10.1097/JTO.0b013e318227816a.

PMID:
21869714
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk